Does Rallies show 13F holders for TCRX?

Yes. Rallies tracks hedge fund and 13F ownership data for TCRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TCRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TCRX. It does not provide personalized investment advice.

TCRX (TScan Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

TScan Therapeutics, Inc. Common Stock (TCRX) is a publicly traded Healthcare sector company. As of May 21, 2026, TCRX trades at $0.99 with a market cap of $65.35M and a P/E ratio of -1.05. TCRX moved +3.26% today. Year to date, TCRX is -4.37%; over the trailing twelve months it is -17.80%. Its 52-week range spans $0.88 to $6.23. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces TCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TCRX stock?

Hedge funds tracked by Rallies that own TCRX include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TScan Therapeutics, Inc. Common Stock.

TCRX Key Metrics

Key financial metrics for TCRX
Metric	Value
Price	$0.99
Market Cap	$65.35M
P/E Ratio	-1.05
EPS	$-0.96
Dividend Yield	0.00%
52-Week High	$6.23
52-Week Low	$0.88
Volume	2
Avg Volume	0
Revenue (TTM)	$9.14M
Net Income	$-124.31M
Gross Margin	0.00%

Top Hedge Funds Holding TCRX

Panagora Asset holds 28.80K shares of TCRX, changed +14.02% as of Mar 31, 2026.

Latest TCRX News

TScan Q1 Net Loss $28.7M, $128.1M Cash Funds Q2 Phase 3 Study — May 6, 2026
TScan to Present CD45-Targeted TCR-T Therapy Abstract at ASGCT Meeting — Apr 27, 2026

Recent TCRX Insider Trades

Lynx1 Capital Management LP bought 6.23K (~$5.60K) on Dec 23, 2025.
Lynx1 Capital Management LP bought 75.50K (~$67.95K) on Dec 22, 2025.
Lynx1 Capital Management LP bought 80.07K (~$71.97K) on Dec 19, 2025.

TCRX Analyst Consensus

6 analysts cover TCRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.

Common questions about TCRX

Who owns TCRX stock?: Hedge funds tracked by Rallies that own TCRX include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TScan Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for TCRX?: Yes. Rallies tracks hedge fund and 13F ownership data for TCRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TCRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TCRX. It does not provide personalized investment advice.